Análises clínicas e imunológicas de estudo de fase II | Sotigalimabe e/ou nivolumabe com quimioterapia no câncer pancreático metastático.
22 Jun, 2022 | 20:43hComunicado de imprensa: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Comentário no Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022